Retevmo (selpercatinib) — Highmark
locally advanced or metastatic RET fusion-positive solid tumors
Initial criteria
- age ≥ 2 years
- diagnosis of locally advanced or metastatic solid tumors
- disease harbors a RET gene fusion as detected by an FDA approved test
- no satisfactory alternative treatments OR tumor(s) have progressed on or following prior systemic treatment
Reauthorization criteria
- prescriber attests that member is tolerating therapy AND has experienced a therapeutic response defined as disease improvement OR delayed disease progression
Approval duration
12 months